In addition, the relationships between serum ApoA-I level and secondary outcomes were also investigated, and the ApoA-I level was found to be associated with CSS (HR: 0.47, 95% CI: 0.19–0.76) in cancers, and the ApoA-I level might be a prognostic indicator for TTR (HR: 0.43, 95% CI: 0.29–0.58) in HCC, LRFS (HR: 0.58, 95% CI: 0.42–0.74) and DMFS (HR: 0.65, 95% CI: 0.41–0.89) in NPC, and DFS (HR: 0.64, 95% CI: 0.43–0.84) in cancers. This evidence concerns the gene APOA1 and hepatocellular carcinoma.